PeptiDream Gelecekteki Büyüme
Future kriter kontrolleri 4/6
PeptiDream kazanç ve gelirin sırasıyla yıllık 33.8% ve 17.5% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 33.8% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 14.9% olacağı tahmin edilmektedir.
Anahtar bilgiler
33.8%
Kazanç büyüme oranı
33.78%
EPS büyüme oranı
| Biotechs kazanç büyümesi | 38.1% |
| Gelir büyüme oranı | 17.5% |
| Gelecekteki özkaynak getirisi | 14.95% |
| Analist kapsamı | Good |
| Son güncelleme | 14 May 2026 |
Gelecekteki son büyüme güncellemeleri
Analiz Makalesi • Feb 18
Analysts Have Lowered Expectations For PeptiDream Inc. (TSE:4587) After Its Latest Results
There's been a notable change in appetite for PeptiDream Inc. ( TSE:4587 ) shares in the week since its yearly report...Analiz Makalesi • Feb 17
Earnings Miss: PeptiDream Inc. Missed EPS By 5.6% And Analysts Are Revising Their Forecasts
It's been a pretty great week for PeptiDream Inc. ( TSE:4587 ) shareholders, with its shares surging 18% to JP¥2,328 in...Analiz Makalesi • Nov 18
PeptiDream Inc. Just Missed Earnings; Here's What Analysts Are Forecasting Now
It's been a good week for PeptiDream Inc. ( TSE:4587 ) shareholders, because the company has just released its latest...Recent updates
Anlatı Güncellemesi • Jun 16
4587: Radiopharmaceutical Pipeline Progress Will Drive Future Upside
Analysts have maintained their ¥4,400 price target on PeptiDream, citing updated assumptions for discount rate, revenue growth, profit margin and future P/E that refine their valuation framework without changing the headline target. What’s in the News for PeptiDream PeptiDream announced first patient dosing in a first in human Phase 0 PET/CT imaging study of Cu-PD-29875 targeting Claudin 18.2 in gastric cancer and gastroesophageal junction cancer.
Anlatı Güncellemesi • Jun 02
4587: Out Licensing Progress And Phase 1 Milestones Will Support Long Term Earnings Visibility
Analysts have trimmed their view on PeptiDream, with the price target moving from ¥2,700 to ¥1,600, as they point to slower than anticipated progress in product out-licensing. What's in the News Asahi Kasei Therapeutics, a collaboration partner of PeptiDream, has started a Phase 1 clinical trial of AK1940, a selective TNFR1 inhibitor discovered using PeptiDream’s PDPS technology.
Anlatı Güncellemesi • May 08
4587: Out Licensing Progress And Autoimmune Pipeline Will Support Future Upside
Analysts have trimmed their price target on PeptiDream to ¥1,600 from ¥2,600, citing slower than expected progress in product out licensing and adjustments to fair value, discount rate, revenue growth, profit margin and future P/E assumptions. Analyst Commentary Bearish analysts are flagging that the lower ¥1,600 price target reflects reduced confidence in how quickly PeptiDream can execute on its product out licensing plans and convert its pipeline into revenue.Anlatı Güncellemesi • Apr 23
4587: Out Licensing Milestones Will Eventually Support Stronger Long Term Earnings Visibility
Analysts have reduced their price target on PeptiDream to ¥1,600 from ¥2,700, citing slower than expected progress in product out-licensing as the main reason for the adjustment. Analyst Commentary Bullish Takeaways Bullish analysts still see value at the revised price target of ¥1,600, arguing that expectations now better reflect the current pace of out-licensing activity.Anlatı Güncellemesi • Apr 08
4587: Out Licensing Progress Will Support Stronger Long Term Earnings Visibility
Analysts have lowered their price target on PeptiDream to ¥2,825 from ¥3,008, citing slightly reduced fair value assumptions following slower than expected product out licensing, as reflected in updated discount rate, revenue growth, profit margin, and future P/E inputs. Analyst Commentary Recent research points to a more cautious stance on PeptiDream, with rating and target price adjustments linked mainly to timing risks around product out licensing.Anlatı Güncellemesi • Mar 25
4587: Out Licensing Progress And 2026 Earnings Targets Will Drive Future Upside
Analysts have modestly raised their fair value estimate for PeptiDream to ¥4,400 from ¥4,255, citing updated assumptions around discount rate, revenue growth, profit margin, and forward P/E, even as some have turned more cautious with a lower Street price target of ¥1,600 reflecting slower than expected product out licensing. Analyst Commentary Recent Street commentary highlights a mix of caution on timing of product out licensing and incremental confidence in PeptiDream's long term potential, reflected in the modest lift in fair value estimates despite a lower Street price target concentrated around ¥1,600.Anlatı Güncellemesi • Mar 10
4587: Oral Autoimmune Pipeline And siRNA Milestones Will Support Stronger Long Term Outlook
Analysts now set their PeptiDream price target at ¥3,008, down slightly from ¥3,033, reflecting updated assumptions around discount rate, revenue growth, profit margin, and future P/E. What's in the News PeptiDream issued consolidated earnings guidance for the fiscal year ending December 31, 2026, with expected revenue of ¥32,000 million, core operating profit and operating profit of ¥4,600 million, and profit attributable to owners of parent of ¥3,000 million (Corporate guidance).Anlatı Güncellemesi • Feb 24
4587: Expanded Oral Pipeline And 2026 Milestones Will Drive Future Upside Potential
Analysts have slightly adjusted their price target on PeptiDream to ¥4,255 from ¥4,281 to reflect updated views on fair value, alongside refreshed assumptions for revenue growth, profit margin, discount rate and future P/E. What's in the News PeptiDream issued consolidated earnings guidance for the fiscal year ending December 31, 2026, expecting revenue of ¥32,000 million, core operating profit and operating profit of ¥4,600 million, and profit attributable to owners of parent of ¥3,000 million.Analiz Makalesi • Feb 18
Analysts Have Lowered Expectations For PeptiDream Inc. (TSE:4587) After Its Latest Results
There's been a notable change in appetite for PeptiDream Inc. ( TSE:4587 ) shares in the week since its yearly report...Anlatı Güncellemesi • Feb 09
4587: Oral Autoimmune Pipeline Progress Will Drive Stronger Long Term Outlook
Analysts have trimmed their price target on PeptiDream to reflect a fair value of ¥3,033, down from ¥3,271, as they factor in slightly softer revenue growth and profit margin assumptions, along with a modestly higher discount rate and P/E multiple outlook. What's in the News PeptiDream reported a revision to its fiscal year 2025 guidance, now expecting revenue of ¥18,000 million instead of ¥49,000 million, with an operating loss of ¥5,400 million and a loss attributable to owners of parent of ¥4,000 million, citing delays in anticipated milestones and partnering deals including its oral myostatin program.Anlatı Güncellemesi • Jan 26
4587: Milestone Progress In RNAi Delivery Platform Will Support Future Upside
Analysts now mark their fair value estimate for PeptiDream at ¥2,600, up from ¥2,500, reflecting adjustments to discount rates, revenue growth assumptions, profit margins, and a higher future P/E multiple. What's in the News PeptiDream reported a preclinical development milestone in its collaboration with Alnylam Pharmaceuticals, supporting a modular platform for precision siRNA delivery using macrocyclic peptides to target organs beyond the liver, with associated milestone payments and potential future royalties from Alnylam products (Key Developments).Anlatı Güncellemesi • Jan 12
4587: Expanded Pipeline Milestones Will Drive Future Upside Potential
Analysts have reduced their price expectations for PeptiDream, reflecting updated assumptions for slightly lower revenue growth and profit margins, along with a higher future P/E multiple. Together, these changes reduce the implied upside from prior targets on a discounted cash flow basis.Anlatı Güncellemesi • Dec 17
4587: Rebound In Partnering Revenues Will Drive Strong Upside Potential
Analysts have trimmed their price target on PeptiDream from ¥4,830 to ¥4,281, reflecting a slightly higher discount rate, even as they modestly raise long term revenue growth and profit margin assumptions and apply a lower future P E multiple. What's in the News PeptiDream sharply cut its FY25 revenue guidance to JPY 18 billion from JPY 49 billion, and now expects an operating loss of JPY 5.4 billion instead of a JPY 21.6 billion profit, as milestone and partnering revenues shift into FY26 (company guidance).Analiz Makalesi • Dec 04
This Just In: Analysts Are Boosting Their PeptiDream Inc. (TSE:4587) Outlook for Next Year
Shareholders in PeptiDream Inc. ( TSE:4587 ) may be thrilled to learn that the analysts have just delivered a major...Anlatı Güncellemesi • Dec 03
4587: Radiopharmaceutical Pipeline Progress Will Drive Stronger Long Term Outlook
Analysts have modestly reduced their price target on PeptiDream from ¥3,414 to ¥3,271 as they incorporate a slightly higher discount rate, even as they update their assumptions to reflect stronger revenue growth, improved profitability, and a lower future P/E multiple. What's in the News PeptiDream, PDRadiopharma, and Curium have initiated a registrational Phase 2 clinical trial in Japan for 64Cu-PSMA-I&T, a PET radiopharmaceutical targeting PSMA expressed on prostate cancer cells (Key Developments).Analiz Makalesi • Oct 05
Is PeptiDream (TSE:4587) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Anlatı Güncellemesi • Sep 05
AI Discovery And Peptide Pipeline Will Expand Horizons
With both the discount rate and future P/E multiple showing only negligible movement, there has been no material change to PeptiDream's consensus analyst fair value, which remains steady at ¥3414. Valuation Changes Summary of Valuation Changes for PeptiDream The Consensus Analyst Price Target remained effectively unchanged, at ¥3414.Analiz Makalesi • Jun 23
PeptiDream (TSE:4587) Seems To Use Debt Rather Sparingly
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analiz Makalesi • Apr 17
Here's Why We Think PeptiDream (TSE:4587) Might Deserve Your Attention Today
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Yeni Anlatı • Mar 10
Advancements In Radiopharmaceutical Pipeline And Novartis Deal Will Drive Future Success
Expansion of deals and strategic partnerships positions PeptiDream for substantial future revenue growth from clinical advancements and imaging collaborations.Analiz Makalesi • Mar 08
PeptiDream (TSE:4587) Has A Rock Solid Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analiz Makalesi • Feb 19
Bullish: Analysts Just Made A Decent Upgrade To Their PeptiDream Inc. (TSE:4587) Forecasts
Shareholders in PeptiDream Inc. ( TSE:4587 ) may be thrilled to learn that the analysts have just delivered a major...Analiz Makalesi • Feb 17
Earnings Miss: PeptiDream Inc. Missed EPS By 5.6% And Analysts Are Revising Their Forecasts
It's been a pretty great week for PeptiDream Inc. ( TSE:4587 ) shareholders, with its shares surging 18% to JP¥2,328 in...Analiz Makalesi • Feb 14
PeptiDream Inc.'s (TSE:4587) Price Is Out Of Tune With Earnings
When close to half the companies in Japan have price-to-earnings ratios (or "P/E's") below 13x, you may consider...Analiz Makalesi • Dec 22
Are Investors Undervaluing PeptiDream Inc. (TSE:4587) By 39%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, PeptiDream fair value estimate is JP¥4,230 PeptiDream is...Analiz Makalesi • Nov 21
PeptiDream's (TSE:4587) Performance Is Even Better Than Its Earnings Suggest
Even though PeptiDream Inc.'s ( TSE:4587 ) recent earnings release was robust, the market didn't seem to notice...Analiz Makalesi • Nov 18
PeptiDream Inc. Just Missed Earnings; Here's What Analysts Are Forecasting Now
It's been a good week for PeptiDream Inc. ( TSE:4587 ) shareholders, because the company has just released its latest...Analiz Makalesi • Nov 15
Is PeptiDream (TSE:4587) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analiz Makalesi • Oct 31
PeptiDream Inc.'s (TSE:4587) Price Is Out Of Tune With Earnings
When close to half the companies in Japan have price-to-earnings ratios (or "P/E's") below 13x, you may consider...Analiz Makalesi • Oct 15
Do PeptiDream's (TSE:4587) Earnings Warrant Your Attention?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analiz Makalesi • Aug 29
PeptiDream Inc. (TSE:4587) Shares Could Be 37% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, PeptiDream fair value estimate is JP¥4,180 Current share price...Analiz Makalesi • Aug 12
PeptiDream Inc. Just Beat Revenue Estimates By 13%
Shareholders of PeptiDream Inc. ( TSE:4587 ) will be pleased this week, given that the stock price is up 11% to...Analiz Makalesi • Jun 30
PeptiDream Inc. (TSE:4587) Surges 27% Yet Its Low P/S Is No Reason For Excitement
PeptiDream Inc. ( TSE:4587 ) shares have continued their recent momentum with a 27% gain in the last month alone...Analiz Makalesi • Jun 02
News Flash: Analysts Just Made A Meaningful Upgrade To Their PeptiDream Inc. (TSE:4587) Forecasts
Celebrations may be in order for PeptiDream Inc. ( TSE:4587 ) shareholders, with the analysts delivering a significant...Analiz Makalesi • Apr 30
PeptiDream Inc.'s (TSE:4587) 42% Price Boost Is Out Of Tune With Revenues
PeptiDream Inc. ( TSE:4587 ) shares have continued their recent momentum with a 42% gain in the last month alone...Analiz Makalesi • Apr 29
Is PeptiDream Inc. (TSE:4587) Trading At A 46% Discount?
Key Insights PeptiDream's estimated fair value is JP¥3,010 based on 2 Stage Free Cash Flow to Equity Current share...Analiz Makalesi • Mar 03
PeptiDream Inc.'s (TSE:4587) 25% Jump Shows Its Popularity With Investors
PeptiDream Inc. ( TSE:4587 ) shareholders would be excited to see that the share price has had a great month, posting a...Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2028 | 50,593 | 14,146 | 18,688 | 21,750 | 7 |
| 12/31/2027 | 46,183 | 12,615 | 16,185 | 22,494 | 7 |
| 12/31/2026 | 44,711 | 12,763 | 23,188 | 28,188 | 7 |
| 3/31/2026 | 19,053 | -3,571 | -5,739 | -4,398 | N/A |
| 12/31/2025 | 18,521 | -3,749 | -15,030 | -13,276 | N/A |
| 9/30/2025 | 17,930 | -5,823 | -14,722 | -12,543 | N/A |
| 6/30/2025 | 19,086 | -5,033 | 13,343 | 15,551 | N/A |
| 3/31/2025 | 46,685 | 14,824 | 13,521 | 15,943 | N/A |
| 12/31/2024 | 46,676 | 15,014 | 21,626 | 23,844 | N/A |
| 9/30/2024 | 47,773 | 17,115 | 25,068 | 27,078 | N/A |
| 6/30/2024 | 55,419 | 21,689 | -780 | 992 | N/A |
| 3/31/2024 | 27,974 | 2,441 | 1,228 | 2,760 | N/A |
| 12/31/2023 | 28,712 | 3,035 | 11,052 | 12,420 | N/A |
| 9/30/2023 | 38,187 | 11,281 | 9,213 | 10,512 | N/A |
| 6/30/2023 | 31,254 | 7,956 | 7,397 | 8,696 | N/A |
| 3/31/2023 | 31,396 | 8,135 | 3,748 | 7,663 | N/A |
| 12/31/2022 | 26,852 | 7,554 | -4,057 | -82 | N/A |
| 9/30/2022 | 12,811 | 57 | -5,082 | -1,376 | N/A |
| 6/30/2022 | 11,511 | 1,705 | -2,483 | 1,687 | N/A |
| 3/31/2022 | 8,326 | 2,341 | 421 | 1,929 | N/A |
| 12/31/2021 | 9,366 | 3,606 | 5,440 | 6,655 | N/A |
| 9/30/2021 | 15,607 | 7,110 | 5,229 | 6,447 | N/A |
| 6/30/2021 | 11,449 | 4,329 | 4,869 | 5,368 | N/A |
| 3/31/2021 | 12,743 | 5,226 | 5,643 | 6,111 | N/A |
| 12/31/2020 | 11,677 | 4,448 | 1,146 | 1,733 | N/A |
| 12/31/2019 | 2,075 | -977 | N/A | 484 | N/A |
| 6/30/2019 | 7,217 | 2,770 | N/A | 4,481 | N/A |
| 6/30/2018 | 6,427 | 2,335 | N/A | 1,023 | N/A |
| 3/31/2018 | 4,616 | 895 | N/A | 623 | N/A |
| 9/30/2017 | 4,271 | 962 | N/A | 517 | N/A |
| 6/30/2017 | 4,896 | 1,891 | N/A | 1,531 | N/A |
| 3/31/2017 | 3,064 | 769 | N/A | 1,095 | N/A |
| 12/31/2016 | 4,457 | 1,685 | N/A | 2,338 | N/A |
| 9/30/2016 | 4,735 | 1,823 | N/A | 2,844 | N/A |
| 6/30/2016 | 4,328 | 1,581 | N/A | 1,533 | N/A |
| 3/31/2016 | 4,620 | 1,976 | N/A | 2,027 | N/A |
| 12/31/2015 | 3,121 | 1,203 | N/A | 1,216 | N/A |
| 9/30/2015 | 2,722 | 1,063 | N/A | 834 | N/A |
| 6/30/2015 | 2,474 | 1,004 | N/A | 1,386 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: 4587 önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 0.8% ) daha hızlı bir büyüme olarak değerlendiriliyor.
Kazançlar ve Piyasa: 4587 önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.
Yüksek Büyüme Kazançları: 4587 önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.
Gelir ve Pazar: 4587 şirketinin gelirinin (yıllık 17.5% ) JP pazarından (yıllık 6.5% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Geliri: 4587 şirketinin gelirinin (yıllık 17.5% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: 4587 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 14.9 %).
Büyüyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/06/29 14:24 |
| Gün Sonu Hisse Fiyatı | 2026/06/29 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
PeptiDream Inc. 14 Bu analistlerden 7, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Shan He | Bernstein |
| Hidemaru Yamaguchi | Citigroup Inc |
| Kazuaki Hashiguchi | Daiwa Securities Co. Ltd. |